Navigation Links
Human Genome Sciences Modifies Dosing in Achieve Trials of Albuferon(R)
Date:1/23/2008

ROCKVILLE, Md., Jan. 23 /PRNewswire-FirstCall/ -- Human Genome Sciences Inc. (Nasdaq: HGSI) announced today that it will modify the dosing in one arm of each of its ACHIEVE clinical trials of Albuferon(R) (albinterferon alfa-2b) for chronic hepatitis C. Patients in the Phase 3 trials who have been receiving the 1200-mcg dose will now receive a 900-mcg dose. The change is based on recommendations made by the studies' independent Data Monitoring Committee (DMC). HGS continues to expect to have all Phase 3 data available by spring 2009 to support the filing of global marketing authorization applications by fall 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO )

"For some time we have viewed the 900-mcg dose administered every two weeks as the most likely marketed dose of Albuferon," said H. Thomas Watkins, President and Chief Executive Officer, HGS. "The 900-mcg dose demonstrated comparable efficacy and safety to Pegasys in Phase 2 - with half the injections, improvements in quality of life and fewer missed days of work during treatment. We continue to believe that Albuferon could become the market-leading interferon for the treatment of hepatitis C if Phase 2 900-mcg results are confirmed in Phase 3."

Consistent with its charter, the DMC routinely reviews all adverse events for each treatment group. Serious pulmonary adverse events, while expected and rare during interferon therapy, were higher in the treatment group receiving 1200-mcg Albuferon administered every two weeks. The DMC did not express any safety concerns about the 900-mcg dose of Albuferon. Based on the DMC's review and conclusions, the patients receiving a 12
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Study Reports Successful Cloning of Human Embryo Using Adult DNA
2. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
3. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
4. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
5. U.S. Department of Health and Human Services Completes Funding of 2006 Contract Award to CSCs DVC and Baxter
6. Two Major Studies Show: Human Pluripotent Stem Cells without Cloning or Destroying Embryo
7. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
8. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
9. Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
10. Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C
11. Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... RALEIGH, N.C. , April 17, 2015 /PRNewswire/ ... of the Integrated Embolic Protection™ filter platform for ... completion of a $5.6 million Series B financing ... stage venture firm with a focus on medical ... medicine. The round also included Mountain Group Partners, ...
(Date:4/17/2015)... -- AbbVie Inc. ("AbbVie") (NYSE / CHX / Euronext Paris / ... of its exchange offer to acquire all of the outstanding ... New York City time, on May ... also voluntarily withdrew its initial Notification and Report Form under ... FTC with additional time to review the proposed transaction.  A ...
(Date:4/17/2015)... 17, 2015 Inivata, a ... that their presence at the 2015 American Association for Cancer ... co-founder Nitzan Rosenfeld and a poster presentation. ... th - 22 nd . The presentation, ... , forms part of a session on ...
Breaking Medicine Technology:Contego Medical Closes $5.6 Million in Series B Funding 2Contego Medical Closes $5.6 Million in Series B Funding 3AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. 2AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. 3AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. 4Inivata Co-founder Nitzan Rosenfeld to Present at AACR Annual Meeting 2
... Alberta, Dec. 15, 2011 Fero Industries, Inc. ... Company,s Mexican operating subsidiary, has completed the registration ... federal and local government institutions within Mexico. This ... of certifications, allows the Company to provide coverage ...
... 2011 MedShape, Inc., the industry leader in innovative shape ... a patent from the United States Copyright and Patent Office ... U.S. Patent No. 8,069,858, was granted December 6, 2011 for ... Shape memory polymers are advanced materials that ...
Cached Medicine Technology:Fero Industries, Inc. Achieves First Certified Supplier Status to Distribute Sucanon® in Mexico 2Fero Industries, Inc. Achieves First Certified Supplier Status to Distribute Sucanon® in Mexico 3MedShape, Inc. Awarded U.S. Patent for Deploying Shape Memory Polymer Devices in Medical Applications 2
(Date:4/18/2015)... 18, 2015 Compare-autoinsurance.org has released a ... reliable auto insurance policy . , Clients should ... insurance quotes online is safe and reliable. An insurance ... quotes are displayed on a single web page, so ... , It is now possible to compare online car ...
(Date:4/18/2015)... April 18, 2015 Carinsurancesavings.biz has released ... plans are cheaper during Spring. , Spring ... insurance plan. Drivers should make sure they compare the ... vehicles. Clients can learn more about Spring car insurance ... , Auto insurance quotes are becoming more and more ...
(Date:4/18/2015)... April 18, 2015 "I recognized the ... in healthcare facilities," said an inventor from Cincinnati, Ohio. ... system." , He developed the Slyde Door to offer ... in healthcare facilities. It provides convenient storage space for ... more stretchers available for patients. , This offers ...
(Date:4/18/2015)... April 18, 2015 Review of Ophthalmology ... a ‘Strategies for Success’ program for cataract surgeons attending ... in San Diego, where eye surgeon Jeffrey L. Martin, ... invitation-only event. Dr. Martin is the Managing Partner of ... Ophthalmology chose Dr. Martin to lead this year’s discussion ...
(Date:4/18/2015)... April 18, 2015 Lowcostcarinsuranceprice.com has released ... rates have on auto insurance prices . ... rates of vehicle theft may have to pay more ... liability auto insurance policies can also offer protection against ... now be compared online on a single website: ...
Breaking Medicine News(10 mins):Health News:A Guide For Avoiding Online Auto Insurance Scams! 2Health News:Auto Insurance Plans Are Cheaper During Spring! 2Health News:Dr. Jeffrey Martin Invited to Share Latest Breakthroughs in Cataract Care During Roundtable Discussion at National 2015 ASCRS Meeting In San Diego 2Health News:High Rates Of Car Theft Can Have An Impact on Auto Insurance Prices! 2
... Aug. 7 Duane Reade Holdings, Inc. announced today that ... the "Issuers"), had closed their offering of $300.0 million aggregate ... (the "Notes"). The Notes bear interest at an annual ... representing a yield to maturity of 12.375%. The Notes ...
... children may miss the target, study finds , FRIDAY, ... for children may have to be revised, say researchers ... indicator of high cholesterol in kids. , In 2008, ... screening guidelines that recommended a cholesterol check for children ...
... , NEW YORK, Aug. 7 WebMD Health Corp. (Nasdaq: ... today announced that executives of WebMD are scheduled to participate at the ... at 1:00 p.m. ET. , , Investors, ... audio broadcast of the presentation over the Internet. The broadcast can ...
... But researchers must figure out how to keep new beta ... European scientists have identified a transcription factor that plays a ... beta cells, and the finding could lead to a new ... the researchers found that when a gene called Pax4 is ...
... , MORGANTOWN, W.Va., Aug. 7 The first ... homeless patients are more likely to arrive at the hospital by ... , One-third of homeless patients arrived by ambulance ... the researchers. , , Analyzing almost half a ...
... , OAKLAND, Calif., Aug. 7 California domestic violence ... help keep abuse survivors safe, thanks to a new program created ... , , The program, funded by a $130,000 ... designed to teach domestic violence advocates about the use of new ...
Cached Medicine News:Health News:Duane Reade Holdings, Inc. Announces Closing of Offering of $300 Million of 11.75% Senior Secured Notes Due 2015 2Health News:Duane Reade Holdings, Inc. Announces Closing of Offering of $300 Million of 11.75% Senior Secured Notes Due 2015 3Health News:Cholesterol Screening Shouldn't Rely on Kids' Weight 2Health News:Researchers Produce First Nationwide Study of Homeless in ERs 2Health News:Verizon and California Partnership to End Domestic Violence Launch Program to Help Victims Protect Themselves by Using Technology 2Health News:Verizon and California Partnership to End Domestic Violence Launch Program to Help Victims Protect Themselves by Using Technology 3Health News:Verizon and California Partnership to End Domestic Violence Launch Program to Help Victims Protect Themselves by Using Technology 4
Long handle occluders are approximately 9 inches long....
Basic external reading model....
Manual Lensmeter....
Lightweight, cordless lensmeter....
Medicine Products: